Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ouch: Cipher Maintains Phase III Trial Failure Of Tramadol Will Not Impact NDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Ontario drug maker may have to contend with two other competitors in the synthetic opioid space.
Advertisement

Related Content

Cipher Seeks Meeting With FDA To Discuss Tramadol “Approvable” Letter
Cipher Seeks Meeting With FDA To Discuss Tramadol “Approvable” Letter
FDA Needs Six Months To Review Labopharm’s Once-Daily Tramadol
FDA Needs Six Months To Review Labopharm’s Once-Daily Tramadol
Labopharm Once-Daily Tramadol Is “Approvable”
Labopharm Once-Daily Tramadol Is “Approvable”
CIP-Tramadol Has April 2007 User Fee Date
CIP-Tramadol Has April 2007 User Fee Date
Biovail To Market Tramadol Under Ortho’s Ultram Brand
Labopharm To Pursue FDA Approval For Once-Daily Tramadol

Topics

Advertisement
UsernamePublicRestriction

Register

PS064837

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel